Eligibility to treatment and economic effect of the implementation of the new U.S. or European Society of XXXX /European Society of Cardiology @entity101 guidelines.

@entity1 @entity101 @entity6 @entity740 @entity65
OBJECTIVE: To evaluate the population and economic impact of implementing the new Joint National Committee (JNC) or European Society of @entity101 (ESH)/European Society of Cardiology (ESC) @entity101 guidelines in the Swiss population. METHODS: Cross-sectional, population-based sample (6708 @entity1 ) collected between 2003 and 2006 in the city of Lausanne, Switzerland. Blood pressure categories were defined according to both the JNC (JNC-7 and JNC-8) and the ESH/ESC (2007 and 2013) guidelines. RESULTS: The proportion of @entity1 aged 35-60 years eligible for drug treatment was 25.6% [95% confidence interval (CI) 24.4-26.9%] and 24.8% (95% CI 23.6-26.0%) for the JNC-7 and the JNC-8 guidelines, respectively; for @entity1 aged 60-75 years, the values were 62.3% (95% CI 60.1-64.5%) and 46.8% (95% CI 44.5-49.0%), respectively. Shifting from the JNC-7 to the JNC-8 guidelines would lead to an annual saving of 163.6 million Swiss francs (187.7 million US dollars or 134.5 million European    ). The proportion of @entity1 aged 35-75 years without @entity740 , @entity6 or reported history of @entity65 and eligible for treatment was 30.2% (95% CI 29.0-31.4%) for the ESH/ESC 2007 and 2013 guidelines. For @entity1 with @entity740 , @entity6 or reported history of @entity65 , the values were 73.6% (95% CI 70.8-76.3%) and 55.6% (95% CI 52.5-58.8%), respectively. Shifting from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would lead to an annual saving of 86.9 million Swiss francs (99.5 million US dollars or 71.4 million European    ). CONCLUSION: In Switzerland, shifting from the JNC-7 to the JNC-8 guidelines or from the ESH/ESC 2007 to the ESH/ESC 2013 guidelines would decrease the prevalence of @entity1 eligible for treatment and increase the percentage of treated @entity1 within blood pressure goals. Both strategies lead to potential savings in antihypertensive drug treatment.
